Abstract
The EBV immediate-early gene product, BZLF1, can disrupt viral latency when placed under the control of a strong heterologuous promoter and transfected into EBV-positive B-cells. (1,2). The BZLF1 gene encodes a transactivating function which has been previously shown to stimulate the activity of several different EBV early promoters. It seems likely that the ability of BZLP1 to disrupt viral latency is related to its activation of key EBV genes which are required for productive infection.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Countryman, J., H. Jenson, R. Seibl, H. Wolf, and G. Miller. 1987. J. Virol. 61:3672–3679.
Takada, K., N. Shimizu, S. Sakuma, and Y. Ono. 1986. J. Virol. 57:1016–1022.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 The Humana Press Inc.
About this chapter
Cite this chapter
Kenney, S., Kamine, J., Holley-Guthrie, E., Lin, JC. (1989). Effect of the BZLF1 Transactivator on Different Classes of EBV Promoters. In: Ablashi, D.V., Faggioni, A., Krueger, G.R.F., Pagano, J.S., Pearson, G.R. (eds) Epstein-Barr Virus and Human Disease • 1988. Experimental Biology and Medicine, vol 20. Humana Press. https://doi.org/10.1007/978-1-4612-4508-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4508-7_6
Publisher Name: Humana Press
Print ISBN: 978-1-4612-8852-7
Online ISBN: 978-1-4612-4508-7
eBook Packages: Springer Book Archive